AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-09. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
=== Collagen hybridizing peptides === Collagen, the major structural component of nearly all mammalian tissues, undergoes extensive proteolytic remodeling during developmental states and a variety of life-threatening diseases such as cancer, myocardial infarction, and fibrosis. While degraded collagen could be an important marker of tissue damage, it is difficult to detect and target using conventional tools. As a result, a collagen hybridizing peptide is specifically hybridized to the degraded, unfolded collagen chains, can be used to image degraded collagen and inform tissue remodeling activity in various tissues. Labeled with 5-carboxyfluorescein and biotin, the collagen hybridizing peptide can enable direct localization and quantification of collagen degradation in isolated tissues within pathologic states ranging from osteoarthritis and myocardial infarction, to glomerulonephritis and pulmonary fibrosis, as well as in normal tissues during developmental programs associated with embryonic bone formation and skin aging. The general correlation between the level of collagen remodeling and the amount of denatured collagen in tissue, show that the collagen hybridizing peptide probes can be used across species and collagen types (including type IV collagen), providing a versatile tool for not only pathology and developmental biology research, but also disease diagnosis via histology.
=== Osteogenesis imperfecta (types 1–4) === Mutations in COL1alpha 1 and/or COL1alpha2 are known to cause several different types of osteogenesis imperfecta with the severity of said diseases being related to the type and frequency of the mutations occurring. For further information on COL1's effect in this disease, see Collagen, type 1, alpha 1.
The Legend of Zelda: Breath of the Wild Dark Souls (video game) Grand Theft Auto V The Last of Us Bloodborne Half-Life 2 Tetris Super Mario Galaxy 2 The Legend of Zelda: Ocarina of Time Resident Evil 4 An Edge Special Edition - "the 30th anniversary special edition" - 100 greatest games of Edge's lifetime (2023)
Sources: en.wikipedia.org
== Sources == Of the different forms of vitamin E, gamma-tocopherol (γ-tocopherol) is the most common form found in the North American diet, but alpha-tocopherol (α-tocopherol) is the most biologically active. The U.S. Department of Agriculture (USDA), Agricultural Research Service, maintains a food composition database called FoodData Central. Common naturally occurring vitamin E sources are shown in the table, as are some alpha-tocopherol fortified sources such as ready-to-eat cereals, infant formulas, and liquid nutrition products.
Charles Jerrard. For services to the British Limbless Ex-Service Men's Association in Romford, Essex. Andy Derrick Johnson, Section Leader, Mathematics and Technology Department, Southwark College, London. For services to Education. George Refoy Johnston, Vice Chairman, Eildon Housing Association. For services to Housing. Samuel Hans Johnston, Process and General Supervisory Grade D, Ministry of Defence. Carol Theresa Jones, lately Senior Personal Secretary, the Highways Agency, Department of Transport. David Charles Newhams Jones, lately Journalist, Ashton Reporter. For services to Journalism in Lancashire. David Lloyd Jones, lately Chief Executive, Arfon Borough Council. For services to Local Government. Howard Leslie Jones, Maintenance Technician, Stanlow Manufacturing Complex, Shell UK Ltd. For services to Health and Safety. Ivy Jones. For services to the community in Tayside. Janice Jones. For services to the community, particularly Young Children, in Adamsdown, Cardiff. Robert Meinon Jones. For services to Choral Music in the District of Ffestiniog, Gwynedd. Lieutenant Colonel Robert Ian Hywel-Jones, , Senior Executive Officer, Foreign and Commonwealth Office. Trevor Mostyn Jones. For services to the Environment in North East England. Vera Daisy Jones. For political and public service. Wendy Keene. For political service. Eileen Grace Kelly. For services to the community in Pulborough, West Sussex. Donald Fraser Kennedy, Honorary Chairman, Dalneigh Senior Citizen's Club. For services to Elderly People in Inverness. Richard Leighton Keys.
An eminent historian nominated by the Government of India who shall be Chairman of the Council Eighteen historians nominated by the Government of India; Representative of the University Grants Commission (UGC) Director General of the Archaeological Survey of India Director General of the National Archives of India Four persons to represent government who shall be nominated by the Government of India and which shall include one representative each of the Ministry of Education, the Department of Culture and the Ministry of Finance, and the Member Secretary, who is appointed by the Council of the ICHR on a deputation basis for a period of three years, with the approval of the Ministry of Human Resource Development, Government of India.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.